-
For early massive Hodgkin's lymphoma, after verbutuximab combined with chemotherapy has achieved complete remission, can radiotherapy be reduced or omitted?
Time of Update: 2021-06-02
A number of studies have reported that patients with a short course of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) treatment and PET-negative patients who have not undergone consolidation radiotherapy can achieve minimal disease control, and Survival rates are similar.
-
My wife and I are both "O" blood type, but the baby has ABO hemolytic disease, is it...
Time of Update: 2021-06-02
Determine the mother and child, except for medical examination errors, the next step is to determine the father's blood type.
-
Master the principles of treatment of relapsed or refractory follicular lymphoma
Time of Update: 2021-06-02
Stamp "Read the original", we make progress togetherRituximab maintenance for the treatment of patients with follicular lymphoma: an updated systematic review and meta-analysis of randomized trials.
Stamp "Read the original text", we make progress togetherRituximab maintenance for the treatment of patients with follicular lymphoma: an updated systematic review and meta-analysis of randomized trials.
-
ASCO 2021 Abstract: Legendary Biologics BCMA CAR-T front-line treatment results are positive | Yimai Meng broke the news
Time of Update: 2021-06-02
It is expected to be submitted in the first half of the yearYimai Meng broke the news that CARTITUDE-2 CARTITUDE-2 is one This multi-cohort Phase 2 clinical study (NCT04133636) aims to evaluate the safety and effectiveness of cilta-cel infusion in various clinical settings for patients with multiple myeloma (MM), and to explore the applicability of outpatient medication.
-
Early precursor T-cell acute lymphoblastic leukemia with SET-NUP214 fusion gene and expressing B cell markers
Time of Update: 2021-06-02
Defu Medical Publishing House published the latest article in the International Journal of General Medicine, an early precursor T-cell acute lymphoblastic leukemia with SET-NUP214 fusion gene and expression of B cell markers.
Keywords:adult acute lymphoblastic leukemia, early T-cell precursor, mixed phenotype acute leukemia, breast infiltration, SET-NUP214 fusion gene
-
Accepted again!
Time of Update: 2021-06-02
Recent popular reports from Yimaike ★Reindeer Medical's fully human CD19/CD22 dual-target CAR-T product clinical trial application has been accepted Yimai Meng broke the news ★ASCO&EHA | Genxi Bi
-
Professor Bai Ou: DHL/DEL diagnosis, treatment and progress | Jinling Lymphatic Tumor Forum 2021
Time of Update: 2021-06-02
The results of the CAVALLI study showed that the combination of the Bcl-2 inhibitor Veneclax on the basis of the R-CHOP regimen can significantly improve the CR rate of DHL patients and at the same time improve the PFS of DEL patients.
-
Transplantation choice after first-line induction chemotherapy for PTCL: AutoSCT or AlloSCT?
Time of Update: 2021-06-02
The primary endpoint of the study is EFS, and secondary endpoints include complete remission (CR) rate, disease progression rate, recurrence rate, proportion of patients receiving transplantation, incidence of acute and chronic graft-versus-host disease (GVHD) after AlloSCT, and treatment-related deaths Rate, PFS, OS, security.
-
BK virus-related HC ushered in effective treatment after Allo-HSCT
Time of Update: 2021-06-01
Research method This clinical trial evaluated the third-party BKV CTL with the highest HLA matching degree obtained from 26 healthy donors and infused it into 59 patients who developed BKV-HC after Allo-HSCT to evaluate the treatment.
-
Nat Commun: Improving the diversity of intestinal flora in patients with acute myeloid leukemia after autologous fecal bacteria transplantation
Time of Update: 2021-06-01
The researchers reported on the results of a phase II single-arm, multi-center study, which mainly evaluated data related to autologous fecal microbiota transplantation (AFMT) in 25 AML patients who received intensive chemotherapy and antibiotic therapy.
-
2021 ASCO prospective | Ponatinib third-generation TKI can benefit CP-CML patients
Time of Update: 2021-06-01
Research methods The study included CP-CML patients who were intolerable/resistant to ≥2 TKIs, or had BCR-ABL1 T315I mutations, and were randomly assigned to receive an initial dose of 45 mg per day (cohort A: 45 mg → 15 mg) and 30 mg per day (Cohort B: 30mg→15mg), 15mg per day (Cohort C) PON treatment.
-
NEJM: Autologous lentiviral gene therapy for severe combined immunodeficiency caused by adenosine deaminase deficiency
Time of Update: 2021-06-01
Event-free survival rate of patients in the UK and US cohortsIsolated lentiviral HSPC gene therapy can treat severe combined immunodeficiency caused by adenosine deaminase deficiency.
Human lentiviral HSPC gene therapy can treat severe combined immunodeficiency caused by adenosine deaminase deficiency.
-
"Children's Autoimmune Hemolytic Anemia Diagnosis and Treatment Guidelines (2021 Edition)" released!
Time of Update: 2021-06-01
For warm-antibody AIHA, glucocorticoids usually take effect within 24 to 48 hours, and the treatment response rate is 50% to 80%, but it is easy to relapse when the dose is reduced too quickly or suddenly stopped.
-
Brit J Heamatol: Family aggregation of early-onset hematological malignancies
Time of Update: 2021-05-31
Researchers aim to estimate individuals diagnosed with early-onset HM and their relatives Hodgkin’s lymphoma (HL), non-Hodgkin’s lymphoma Standard Incidence Rate (SIR) and Cumulative Risk of Neoplasia (NHL), Acute Lymphocytic Leukemia/Lymphoma (ALL/LBL) and Acute Myeloid Leukemia (AML).
-
Gastroenterologist must read the book list!
Time of Update: 2021-05-31
cn/ipsen/sporty/show-details/3074/2">digestive Section 2020 ~ 2021 Official Guide Collection 1 part👉 scan code presented medsci.
00 👉 Scan the code to see the end of the article " Gold Standard and Operation Manual for Digestive Endoscopy Diagnosis ""Digestive endoscopy diagnostic gold standard and operating manual" Diagnostic Original price￥41.
-
["Wei" has come] The first Bcl-2 inhibitor Weikelai® has been authorized by the latest CSCO guidelines
Time of Update: 2021-05-23
Professor Ma Jun said, “The new drug VEN has not been clinically approved for less than a year, and it has been included in the new version of the CSCO Guidelines for Diagnosis and Treatment of Hematological Malignancies, adding a powerful'weapon' for hematologists and also for the clinical treatment of AML patients.
-
"The Lancet" publishes preliminary safety data of "mixed inoculation" trial
Time of Update: 2021-05-23
Today, "The Lancet" recently published important data from a large randomized trial in the United Kingdom, by evaluating the combination of AstraZeneca's new crown vaccine ChAdOx1 nCoV-19 and Pfizer/BioNTech's new crown vaccine BNT162b2, and analyzing the local subjects after vaccination And systemic reactions, as well as laboratory blood and biochemical test results, provide preliminary data for the safety of mixed vaccination.
-
Junshi Bio: The clinical trial application of JS103 injection was approved
Time of Update: 2021-05-23
It can catalyze the oxidation of uric acid into allantoin with significantly higher solubility than uric acid.
Or without the treatment of gout, it can reduce blood uric acid by catalyzing the oxidation of uric acid into allantoin, which has a significantly higher solubility than uric acid .
-
Hongri Pharmaceutical: Fasudil Hydrochloride Injection passed the quality and efficacy consistency evaluation of generic drugs...
Time of Update: 2021-05-23
It is understood that fasudil hydrochloride injection and developed by Asahi Kasei and Nagoya University, respectively, in 1995 and launched in Japan in 2001 and listed in China, mainly for Cerebral Vascular spasm spasms caused by the Improvement of symptoms of ischemic cerebrovascular disease.
-
The latest clinical data of Vertex/CRISPR gene editing therapy will be announced
Time of Update: 2021-05-23
Another abstract, code-named EP733, will be published in the video conference, titled "CTX001 for blood transfusion-dependent thalassemia: the ongoing CLIMB Thal-111 study of autologous Crispr-Cas9-modified CD34+ hematopoietic stem and progenitor cells Safety and effectiveness.
